N-hydroxysuccinimidyl-(2-phenyl)ethyl carbonate | 116586-32-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-hydroxysuccinimidyl-(2-phenyl)ethyl carbonate
• 英文别名: N-(phenethyloxycarbonyloxy)succinimide；(S)-2-phenylethyloxy-carbonyloxysuccinimide；(2,5-dioxopyrrolidin-1-yl) 2-phenylethyl carbonate
• CAS: 116586-32-4
• 化学式: C₁₃H₁₃NO₅
• 分子量: 263.25
• InChiKey: AQTLIQLMUFYIQA-UHFFFAOYSA-N

物化性质

• 熔点：
  67-72 °C
• 沸点：
  387.5±35.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-hydroxysuccinimidyl-(2-phenyl)ethyl carbonate 、 H-Lys(Boc)-D-gGlu-Oic-OH 生成 (2S,3aS,7aS)-1-[(4R)-4-[[(2S)-6-amino-2-(2-phenylethoxycarbonylamino)hexanoyl]amino]-4-carboxybutanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
  参考文献：
  名称：

  SAWAYAMA, TADAHIRO;TSUKAMOTO, MASATOSHI;SASAGAWA, TAKASHI;NISHIMURA, KAZU+, CHEM. AND PHARM. BULL., 38,(1990) N, C. 110-115

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N'-二琥珀酰亚胺基碳酸酯 、 苯乙醇 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 6.0h， 以65%的产率得到N-hydroxysuccinimidyl-(2-phenyl)ethyl carbonate
  参考文献：
  名称：

  血管紧张素转化酶抑制剂：N-取代的三肽抑制剂的合成和生物学活性。

  摘要：

  合成了一系列新的高效血管紧张素转化酶（ACE）抑制剂，即1-（N2-取代的L-赖氨酰基-γ-D-谷氨酰基）八氢-1H-吲哚-2-羧酸。在N末端P1 Lys的α-氨基处引入了各种酰基。研究了N2-酰基对体外抑制活性和口服降压作用的影响。发现所有合成的N-酰基三肽都具有约纳摩尔水平的体外抑制活性，并且当口服时，在肾性高血压大鼠中以10 mg / kg的剂量显示出抗高血压功效。其中，化合物7e，g和9f，i，m与依那普利（2a）相比显示出有效且持久的降压作用。还讨论了它们的构效关系。

  DOI：

  10.1248/cpb.38.110

文献信息

• Sulfonamide inhibitors of aspartyl protease
  申请人：Vertex Pharmaceuticals, Incorporated

  公开号：US05585397A1

  公开（公告）日：1996-12-17

  The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

  本发明涉及一类新型磺胺类化合物，其为天冬氨酸蛋白酶抑制剂。在一个实施例中，本发明涉及一类新型HIV天冬氨酸蛋白酶抑制剂，其具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制HIV-1和HIV-2蛋白酶活性，因此，可以有利地用作抗HIV-1和HIV-2病毒的抗病毒剂。本发明还涉及使用本发明的化合物抑制HIV天冬氨酸蛋白酶活性的方法以及筛选具有抗HIV活性的化合物的方法。
• Tripeptide derivatives
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04826814A1

  公开（公告）日：1989-05-02

  There are provided tripeptide compounds represented by the following formula ##STR1## wherein R.sub.1 represents a C.sub.1-10 alkyl group, a C.sub.4-7 cycloalkyl or C.sub.5-7 cycloalkyl-lower alkyl group, a phenyl or phenyl-lower alkyl group in which the benzene ring may optionally be substituted by a substituent selected from halogen, lower alkyl, lower alkoxy, phenyl, methylenedioxy, ethylenedioxy, amino, di(lower alkyl)amino and hydroxy, a naphthyl or naphthyl-lower alkyl group in which the naphthalene ring may optionally be substituted by a substituent selected from halogen, lower alkyl, lower alkoxy and hydroxy, a heterocyclic or heterocyclic-lower alkyl group in which the heterocycle is a saturated or unsaturated 5- or 6-membered ring containing a nitrogen, oxygen or sulfur atom as the hetero atom, and may optionally be substituted by a substituent selected from halogen, lower alkyl, lower alkoxy, amino, di(lower alkyl)amino, hydroxy, oxo and saturated 5- or 6-membered nitrogen-containing heterocyclic group, and further may optionally be fused to a benzene ring, or an imidazolylvinyl group; R.sub.2 represents a hydrogen atom, a C.sub.1-10 alkyl group or a benzyl group; R.sub.3 represents a group of the formula ##STR2## represents a benzene, cyclopentane or cyclohexane ring, R.sub.4 represents a hydrogen atom, a C.sub.1-10 alkyl group or a benzyl group, p is 0 or 1, q is 1, 2, or 3, and X represents a phenyl group which may optionally be substituted by a substituent selected from halogen, lower alkoxy and hydroxy, a C.sub.4-8 cycloalkyl group, or a C.sub.5-7 cycloalkyl group which is fused to a benzene, and Y represents a hydrogen atom or a lower alkyl group, or X and Y, together with the nitrogen and carbon atoms to which they are bonded, forms a 5- or 6-membered heterocycle which may contain a nitrogen, oxygen or sulfur atom, W represents a single bond, --O-- or --NH--, T represents a single bond, ##STR3## and m is 2 or 3, or salts thereof and processes for production thereof. The compounds are useful as antihypertensive agents.

  提供的三肽化合物的化学式如下所示：其中R.sub.1代表C.sub.1-10烷基基团、C.sub.4-7环烷基或C.sub.5-7环烷基-低烷基基团、苯基或苯基-低烷基基团，其中苯环可能被卤素、低烷基、低烷氧基、苯基、亚甲二氧基、乙二氧基、氨基、二(低烷基)氨基和羟基等取代基取代；萘基或萘基-低烷基基团，其中萘环可能被卤素、低烷基、低烷氧基和羟基等取代基取代；杂环或杂环-低烷基基团，其中杂环是饱和或不饱和的含氮、氧或硫原子的5-或6-成员环，可能被卤素、低烷基、低烷氧基、氨基、二(低烷基)氨基、羟基、氧代和饱和的含氮5-或6-成员环取代基取代，并且可能与苯环融合，或者是咪唑乙烯基团；R.sub.2代表氢原子、C.sub.1-10烷基基团或苄基团；R.sub.3代表下式中的基团##STR2## 代表苯、环戊烷或环己烷环，R.sub.4代表氢原子、C.sub.1-10烷基基团或苄基团，p为0或1，q为1、2或3，X代表苯基，可能被卤素、低烷氧基和羟基等取代基取代，C.sub.4-8环烷基，或与苯融合的C.sub.5-7环烷基，Y代表氢原子或低烷基基团，或X和Y连同它们结合的氮和碳原子形成一个含氮、氧或硫原子的5-或6-成员杂环，W代表单键，-O-或-NH-，T代表单键，##STR3## m为2或3，或其盐和生产方法。这些化合物可用作降压药。
• Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
  申请人：——

  公开号：US20030013719A1

  公开（公告）日：2003-01-16

  Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations including their use as antiarrhythmic active compounds, for example, for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutters. Compounds of the invention include compounds of the formula I 1

  本发明涉及正交、间位取代的双芳基化合物、其制备方法、其作为药物的用途以及包括其作为抗心律失常活性化合物的制药制剂，例如用于治疗和预防心房心律失常，例如心房颤动（AF）或心房扑动。本发明的化合物包括式I1的化合物。
• PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES
  申请人：Santi Daniel V.

  公开号：US20110263502A1

  公开（公告）日：2011-10-27

  The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.

  本发明提供了一种允许体内控制和延长药物释放的方法和组合物。这些化合物要么是具有可调节释放速率的前药，要么是药物与大分子结合物，其具有可调节的控制释放速率。
• ORTHO, META-SUBSTITUIERTE BISARYLVERBINDUNGEN, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS MEDIKAMENT SOWIE SIE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1339675A1

  公开（公告）日：2003-09-03